189699-82-9
189699-82-9 結(jié)構(gòu)式
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-U00146 | 189699-82-9 FR-188582 | 189699-82-9 | 1mg | 3000元 |
| 2024/11/08 | HY-U00146 | 189699-82-9 FR-188582 | 189699-82-9 | 5mg | 6000元 |
| 2023/03/20 | HY-U00146 | 189699-82-9 FR-188582 | 189699-82-9 | 10 mg | 10200元 |
常見(jiàn)問(wèn)題列表
|
COX-2 17 nM (IC 50 ) |
In a recombinant human cyclooxygenase (COX) enzyme activity, FR-188582 (FR188582) inhibits COX-2 with an IC 50 value of 17 nM, and the inhibition of prostaglandin (PG) E2 formation by FR188582 isover 6000 times more selective for COX-2 than COX-1.
Oral administration of FR-188582 (0.01-3.2 mg/kg) reverses paw edema in adjuvant arthritic rats and shows a therapeutic effect in a dose-dependent manner with ED 50 values (95% C.L.) of 0.074 (0.00021-0.53) and 0.063 (0.0039-0.31) mg/kg for adjuvant-injected paws and adjuvant-uninjected paws, respectively. The anti-inflammatory effect of FR-188582 (FR188582) is threefold more potent than that of Indomethacin with ED 50 values (95% C.L.) of 0.24 (0.047-1.8) and 0.20 (0.021-0.79) mg/kg for adjuvant-injected paws and adjuvant-uninjected paws, respectively.